Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Thyroid Neoplasms 2Neoplasms 2Melanoma 2Xanthogranuloma, Juvenile 1Wilms Tumor 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Skin Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Neoplasm Metastasis 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Leukemia, Hairy Cell 1Leukemia 1Histiocytosis, Langerhans-Cell 1Histiocytic Sarcoma 1Hepatoblastoma 1Glioma 1Ependymoma 1Craniopharyngioma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Radiotherapy 2Proton Therapy 2tocilizumab 1cobimetinib 1Vemurafenib 1Transurethral Resection of Bladder 1Surgical Procedures, Operative 1Methionine 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Craniopharyngioma × Vemurafenib × Clear all
NCT03224767 2025-02-18

Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

Alliance for Clinical Trials in Oncology

Phase 2 Active not recruiting
24 enrolled
CNS

Craniopharyngioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡